Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records (Q34599640)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records (English)

1 reference

Europe PubMed Central

3 August 2017

type 2 diabetes

0 references

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Patrick J Boyle

1

1 reference

Europe PubMed Central

3 August 2017

Allen Bennett King

2

1 reference

Europe PubMed Central

3 August 2017

Leann Olansky

3

1 reference

Europe PubMed Central

3 August 2017

Albert Marchetti

4

1 reference

Europe PubMed Central

3 August 2017

Helen Lau

5

1 reference

Europe PubMed Central

3 August 2017

Raf Magar

6

1 reference

Europe PubMed Central

3 August 2017

John Martin

7

1 reference

Europe PubMed Central

3 August 2017

publication date

1 March 2002

1 reference

Europe PubMed Central

3 August 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

3 August 2017

24

1 reference

Europe PubMed Central

3 August 2017

3

1 reference

Europe PubMed Central

3 August 2017

378-396

1 reference

Europe PubMed Central

3 August 2017

Nonhypoglycemic effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical significance of peroxisome proliferator-activated receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

An autopsy case of troglitazone-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular injury in a patient receiving pioglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone and hepatic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone and liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985040-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(02)85040-8

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34599640&oldid=1556683409"